"Insulet and Ypsomed Sign Distribution Agreement for Europe: Ypsomed Expected to Expand Market for Insulin Pump Therapy Summary Insulet is a start up company in the insulin delivery market. The company’s product, the Omnipod, which is a disposable insulin pump was approved by the USFDA in January. The company began marketing its product in October 2005. The initial focus of the company was in the Eastern United States and then progressed towards marketing in the entire country. The company received a CE mark for Omnipod in 2009 and this distribution agreement with Ypsomed is to increase its sales and marketing efforts in countries outside the US. BBIC’s analysts mapped a strong deal rationale for this distribution agreement. Insulet, though it had an innovative product, did not make a very huge impact as expected by industry analysts in the US. This was primarily due to its lack of strong distribution network in the diabetes care market in the US. Insulet, in signing an agreement with Ypsomed (which has one of the strongest distribution network for the insulin pump market in Europe) has made a well strategised decision that would help the company expand its market and also gain market share. Scope - Details of the agreement included. - Rationale behind the deal. - Key trends prevalent in the medical equipment market derived from the deal. - Forecast market revenue for the global traditional and disposable insulin pumps market. Reasons to buy - Identify key distribution trends in the medical equipment market. - Track competitor product portfolios and distribution agreements. - Assess future outlook of the companies in question." (Editor in charge ：Roy Huang) |